OKYO Pharma
OKYO
12 hedge funds and large institutions have $10.3M invested in OKYO Pharma in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
796% more capital invested
Capital invested by funds: $1.15M → $10.3M (+$9.14M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
20% more funds holding
Funds holding: 10 → 12 (+2)
13.99% more ownership
Funds ownership: 1.77% → 15.76% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$7.09M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$2.28M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.65M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.14M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$908K |
| 2 |
Renaissance Technologies
New York
|
-$286K |
| 3 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$21.2K |
OKYO Hedge Fund Activity: Q1 2026 in Review
12 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q1 2026, worth a combined $10.3M — up 796% from $1.15M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OKYO positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $7.09M. The largest seller was Dauntless Investment Group, cutting an estimated $908K.
- 12 institutional investors held OKYO Pharma (OKYO) as of Q1 2026, up from 10 in Q4 2025.
- Funds reported $10.3M of OKYO Pharma stock for Q1 2026, up 796% quarter-over-quarter.
- 4 funds opened new OKYO Pharma positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest OKYO Pharma buyer in Q1 2026 was Woodline Partners, an estimated $7.09M added.
- The largest OKYO Pharma seller in Q1 2026 was Dauntless Investment Group, an estimated $908K sold.
Based on aggregated 13F filings for Q1 2026.